Brief: Eiger Reports Publication Of Positive Results Of Avexitide In Children With Congenital Hyperinsulinism
25/04/2022 13:12
April 25 (Reuters) - Eiger BioPharmaceuticals Inc EIGR.O :
* EIGER ANNOUNCES PUBLICATION OF POSITIVE PHASE 2 RESULTS OF
AVEXITIDE IN CHILDREN WITH CONGENITAL HYPERINSULINISM AND
INITIATION OF PHASE 3 PROGRAM
* EIGER BIOPHARMACEUTICALS INC - EIGER PLANS TO INITIATE
AVEXITIDE
PHASE 3 REGISTRATIONAL PROGRAM BY YEAR-END 2022
* EIGER- PHASE 2 STUDY DEMONSTRATING AVEXITIDE SIGNIFICANTLY
REDUCED HYPOGLYCEMIA IN CHILDREN WITH CONGENITAL HYPERINSULINISM
PUBLISHED IN DIABETES CARE
Source text for Eikon: ID:nPn5Cl7Pja
Further company coverage: EIGR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eiger Biopharmaceuticals
See all newsBrief: Eiger Biopharmaceuticals On Sept 5, Bankruptcy Court Entered Order Confirming Fifth Amended Joint Plan Of Liquidation Of Co & Its Debtor Affiliates
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar
Brief: Eiger Biopharmaceuticals And Amylyx Entered Into An Asset Purchase Agreement
Eiger BioPharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Eiger BioPharmaceuticals Inc expected to post a loss of $7.50 a share - Earnings Preview